Acelot is the first company to develop poly-disaggregator drugs that treat the multiple protein aggregate targets found within a single neurodegenerative patient, such as beta amyloid, tau, alpha synuclein, and TDP-43. We are targeting protein aggregates in neurodegenerative diseases by breaking the existing dogma of antibody approaches. Our small molecule approach is cell-penetrant, brain-penetrant, and treats multiple targets. Acelot's compounds are discovered through a unique machine learning platform that incorporates novel protein aggregate assay data. Acelot is a seed stage biotechnology company founded by UC Santa Barbara Computer Science Professor Ambuj Singh.